When to consider endoscopic ablation therapy for Barrett's esophagus

Area of Science:

• Gastroenterology
• Endoscopic Therapeutics
• Barrett's Esophagus Management

Background:

• Barrett's esophagus is a precancerous condition requiring effective management.
• Endoscopic ablative therapies have emerged as crucial treatment options.

Purpose of the Study:

• To review and evaluate endoscopic ablative therapies for Barrett's esophagus.
• To assess patient selection criteria and optimal timing for these interventions.

Main Methods:

• Systematic review of recent literature on ablative therapies for Barrett's esophagus.
• Analysis of data from cohort and case series studies, primarily focusing on radiofrequency ablation (RFA) and photodynamic therapy (PDT).

Main Results:

• Radiofrequency ablation (RFA) demonstrates high efficacy (over 90% reversion for nondysplastic/low-grade, over 80% for high-grade dysplasia) and durability (2-5 years).
• RFA is well-tolerated with manageable side effects like chest pain; stricture rates are low (0-8%).
• Photodynamic therapy (PDT) shows similar mortality to surgery but has higher stricture rates and lower efficacy compared to RFA.

Conclusions:

• Radiofrequency ablation (RFA) is the intervention of choice for high-grade dysplasia in Barrett's esophagus due to its efficacy, safety, and cost-effectiveness.
• RFA may benefit younger patients or those with long-segment/multifocal low-grade dysplasia.
• The value of ablating nondysplastic Barrett's esophagus remains uncertain; PDT is generally less favorable than RFA.